🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07709143
Recruiting Observational

MRI Performance and Risk Factors in Bilateral Vestibular Hypofunction

NCT07709143 · tracked via the Priya Life Science China tracker
Sponsor
Shanghai 6th People's Hospital
Phase
Observational
Started
2024-10-11
Last updated
2026-07-16

Condition(s) studied

Bilateral Vestibular HypofunctionBilateral VestibulopathyPresbyvestibulopathy

Investigational drug(s) / intervention(s)

Multimodal Neuroimaging and Vestibular Function Assessment

Multimodal Neuroimaging and Vestibular Function Assessment: Participants will undergo multimodal neuroimaging and vestibular function assessments, including resting-state functional magnetic resonance imaging (rs-fMRI), diffusion tensor imaging (DTI), diffusion kurtosis imaging (DKI), and standardized vestibular function tests. Vestibular assessments include videonystagmography (VNG), caloric test (CT), sinusoidal harmonic acceleration test (SHAT), video head impulse test (vHIT), vestibular evoked myogenic potentials (VEMP), and sensory organization test (SOT). Participant-reported clinical scales and laboratory examinations will also be collected to evaluate the relationship between vestibular dysfunction, brain function, biochemical variables, quality of life, and BVH severity.

Study summary

Bilateral vestibular hypofunction (BVH) is a chronic disorder in which the balance organs or vestibular pathways on both sides do not work normally. People with BVH may experience unsteadiness, blurred or unstable vision during head movement, difficulty walking, and an increased risk of falls. At present, there are limited targeted medical treatments, and the reasons why symptoms are severe in some patients but mild in others are not fully understood.

This prospective, multicenter, cross-sectional study will investigate the relationships among vestibular function, brain structure and function, blood biomarkers, patient-reported symptoms, and disease severity in people with BVH. The study will enroll approximately 120 participants from five medical centers in China, including about 80 patients with BVH and 40 age-matched healthy controls.

Participants will undergo vestibular function tests, including videonystagmography, caloric testing, sinusoidal harmonic acceleration testing, video head impulse testing, vestibular evoked myogenic potentials, and sensory organization testing. Brain imaging will include resting-state functional magnetic resonance imaging, diffusion tensor imaging, and diffusion kurtosis imaging. Participants will also complete questionnaires related to dizziness, anxiety and depression, daily activities, and symptom severity, and blood samples will be collected for biochemical and inflammatory marker testing.

The main hypothesis is that BVH severity is associated with measurable changes in vestibular function, brain functional connectivity and microstructure, inflammatory or metabolic biomarkers, and patient-reported quality of life. By combining clinical testing, neuroimaging, laboratory measures, and symptom scales, this study aims to improve understanding of the mechanisms of BVH and to support future development of more individualized diagnostic and rehabilitation strategies.

Eligibility

Sex
ALL
Min age
16 Years
Max age
Healthy volunteers
Accepted
Inclusion Criteria: 1. Sex unrestricted, age over 16 years old. 2. Patients meeting the diagnostic criteria for bilateral vestibulopathy (BVP) and presbyvestibulopathy (PVP) 3. Participants or their legal representatives, who comprehensively understand the research purpose, demonstrate sufficient compliance with the study protocol, have the ability to communicate and cooperate, and have signed the informed consent form. Exclusion Criteria: 1. Administration of medications potentially affecting cerebral function, including psychotropic drugs (antidepressants, anxiolytics) or prolonged anti-vertigo medication usage. 2. Presence of severe cardiovascular or systemic medical conditions, organ dysfunction, or significant mobility impairments. 3. Significant local or systemic diseases, or psychiatric disorders causing cognitive impairment, specifically schizophrenia, major depressive disorder, or generalized anxiety disorder. 4. Pregnant or lactating women. 5. Participation in alternative pharmaceutical or medical device clinical trials within the preceding 3-month period. 6. Clinically significant head movement restrictions. 7. Subjects assessed by investigators as unsuitable for study participation. 8. Individuals with contraindications for MRI, including cardiac pacemakers, implanted electronic devices, claustrophobia, metallic implants incompatible with magnetic resonance imaging and medications potentially compromising MRI scan safety.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
shanghai Jiao Tong University School of Medicine Affiliated Sixth People's Hospital Shanghai Shanghai Municipality Recruiting

More Shanghai 6th People's Hospital trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07709143 on ClinicalTrials.gov ↗ ← All trials in China